Aspira Women's Health Inc. — fact timeline

Aspira Women's Health Inc. amended Existing Warrants Amendment Agreement with holders of existing warrants valued at Amend existing warrants covering 366,664 shares: reduce exercise price from $13.20 to $4.13 per shar (effective 2024-01-26).

“The Company has also agreed that certain existing warrants to purchase up to an aggregate of 366,664 shares at an exercise price of $13.20 per share and a termination date of August 25, 2027, will be amended, effective upon the closing of the Offering, so that the amended warrants will have a reduced exercise price of $4.13 per share and a new termination date of January 26, 2029.”

Aspira Women's Health Inc. entered into Form of Purchase Warrant with single healthcare focused institutional investor and others valued at Warrant to purchase up to 1,571,000 shares at $4.13 per share; exercisable six months after issuance (effective 2024-01-24).

“The Purchase Warrants will have an exercise price of $4.13 per share, and will be exercisable beginning six months after issuance and will expire 5 years from the initial exercise date.”

Aspira Women's Health Inc. entered into Form of Pre-Funded Warrant with single healthcare focused institutional investor and others valued at Pre-funded warrant to purchase up to 200,000 shares at $0.0001 exercise price; exercisable at any ti (effective 2024-01-24).

“g descriptions of the terms of the Placement Agency Agreement, the Securities Purchase Agreement, Pre-Funded Warrants and Purchase Warrants are each qualified in their entirety by reference to the Placement Agency Agreement, the Securities Purchase Agreement, form of Pre-Funded Warrant and form of Purchase Warrant, respectively, which are attached as Exhibit 1.1, Exhibit 10.1, Exhibit 4.1 and Exhibit 4.2 hereto, respectively, and incorporated by reference herein.”

Aspira Women's Health Inc. entered into Securities Purchase Agreement with single healthcare focused institutional investor, Nicole Sandford, and certain existing shareholders valued at Issuance of 1,368,600 shares at $3.50 per share and 2,400 shares at $4.255 per share, plus warrants; (effective 2024-01-24).

“On January 24, 2024, Aspira Women’s Health Inc. (the “Company” or “Aspira”) entered into a placement agency agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (“AGP”) and a securities purchase agreement (the “Securities Purchase Agreement,” and together with the Placement Agency Agreement, the “Agreements”) with a single healthcare focused institutional investor alongside participation from Nicole Sandford, CEO of Aspira, as well as certain existing shareholders of the Company (collectively, the “Purchasers”), relating to the issuance and sale of 1,371,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and pre-funded warrants to purchase 200,000 shares of Common Stock (the “Pre-Funded Warrants”), in a registered direct offering, together with accompanying warrants to purchase 1,571,000 shares of Common Stock (the “Purchase Warrants”, and together with the Pre-Funded Warrants, the “Warrants”) in a concurrent private”

Aspira Women's Health Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at Placement agent fee of 7.0% of gross proceeds from the offering (effective 2024-01-24).

“On January 24, 2024, Aspira Women’s Health Inc. (the “Company” or “Aspira”) entered into a placement agency agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (“AGP”) and a securities purchase agreement (the “Securities Purchase Agreement,” and together with the Placement Agency Agreement, the “Agreements”) with a single healthcare focused institutional investor alongside participation from Nicole Sandford, CEO of Aspira, as well as certain existing shareholders of the Company (collectively, the “Purchasers”), relating to the issuance and sale of 1,371,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and pre-funded warrants to purchase 200,000 shares of Common Stock (the “Pre-Funded Warrants”), in a registered direct offering, together with accompanying warrants to purchase 1,571,000 shares of Common Stock (the “Purchase Warrants”, and together with the Pre-Funded Warrants, the “Warrants”) in a concurrent private”

Aspira Women's Health Inc. amended certain existing warrants (effective 2024-01-26).

“The Company has also agreed that certain existing warrants to purchase up to an aggregate of 366,664 shares at an exercise price of $13.20 per share and a termination date of August 25, 2027, will be amended, effective upon the closing of the Offering, so that the amended warrants will have a reduced exercise price of $4.00 per share and a new termination date of January 26, 2029.”

Aspira Women's Health Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at 7.0% of the aggregate gross proceeds generated from the Offering (effective 2024-01-24).

“On January 24, 2024, Aspira Women’s Health Inc. (the “Company” or “Aspira”) entered into a placement agency agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (“AGP”) and a securities purchase agreement”

Aspira Women's Health Inc. entered into Securities Purchase Agreement with a single healthcare focused institutional investor alongside participation from Nicole Sandford, CEO of Aspira, as well as certain existing shareholders of the Company valued at gross proceeds to the Company from the Offering are expected to be approximately $5.5 million (effective 2024-01-24).

“) with a single healthcare focused institutional investor alongside participation from Nicole Sandford, CEO of Aspira, as well as certain existing shareholders of the Company”

Jannie Herchuk was appointed as Chair of the Board at Aspira Women's Health Inc..

“Following Dr. Jordan’s resignation, the Board appointed Jannie Herchuk as the Chair of the Board and Lynn O’Connor Vos to the Audit Committee, in each case effective December 27, 2023.”

Veronica G.H. Jordan resigned as Director and Chair of the Board at Aspira Women's Health Inc..

“On December 21, 2023, Veronica G.H. Jordan, Ph.D. resigned from the board of directors (the “ Board ”) of Aspira Women’s Health Inc., including as chair of the Board, chair of the compensation committee of the Board and as a member of the audit committee of the Board (the “Audit Committee”), effective immediately.”

Aspira Women's Health Inc. reported the three and nine months ended September 30, 2023 results: revenue $2,217,000.

“leading sales at Sema4Genomics and Sonic Reference Laboratory, Inc.  Third Quarter 2023 Financial Highlights Product revenue for the three months ended September 30, 2023, was $2,217,000, an increase of 9%, compared to $2,037,000 for the same period in 2022. The increase in revenue was primarily due to an increase in OvaSuite test volume compared to the prior year,”

Aspira Women's Health Inc. reported that prior financial statements should not be relied upon.

“the Audit Committee of the Board of Directors (the “Audit Committee”) of Aspira Women’s Health Inc. (the “Company”) and the Company’s management determined that its previously issued financial statements in its Annual Report on Form 10-K for the year ended December 31, 2022, as well as the previously filed Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022 (collectively, the “Prior Period Financial Statements”), should be restated and should no longer be relied upon”

Ryan Phan resigned as Chief Scientific and Operating Officer at Aspira Women's Health Inc..

“On August 3, 2023, Dr. Ryan Phan, the Chief Scientific and Operating Officer of Aspira Women’s Health Inc., (the “Company), notified the Company that he will resign from these roles with the Company effective September 15, 2023.”

Aspira Women's Health Inc. reported financial results for the three and six months ended June 30, 2023.

“On August 14, 2023, Aspira Women’s Health Inc. (the “Company”) issued a press release reporting financial results for the three and six months ended June 30, 2023.”

Aspira Women's Health Inc. reported second quarter ended June 30, 2023 results: revenue $2.5 million. Guidance lowered.

“(EX-99.1) --- 2023-08-14 8K Ex 991 Exhibit 99 .1 Aspira Women’s Health ® Reports Second Quarter 2023 Financial Results  Continued growth trend with second quarter revenue of $2.5 million, an increase of 23% over the second quarter of 2022. OvaSuite volume of 6,289 units, an increase of 16% year-over-year Achieved cash used in operations of $3.4 million, a”

Dr. Ryan Phan resigned as Chief Scientific and Operating Officer at Aspira Women's Health Inc..

“On August 3, 2023, Dr. Ryan Phan notified Aspira Women’s Health Inc., (the “Company”), of his intent to resign as Chief Scientific and Operating Officer of the Company effective September 15, 2023.”

Aspira Women's Health Inc. entered into Securities Purchase Agreement with several investors (the Purchasers) valued at approximately $4.7 million (effective 2023-07-20).

“On July 20, 2023, Aspira Women’s Health Inc., or Aspira, entered into a securities purchase agreement, or the Purchase Agreement, with several investors, or the Purchasers, relating to the issuance and sale of an aggregate of 1,694,820 shares of its common stock, par value $0.001 per share, or the Offering.”

Aspira Women's Health Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

“July 11, 2023, Aspira Women’s Health Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days prior to the date of the Notice, the Company’s minimum Market Value of Listed Securities was below the minimum of $35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq has provided the Compan”

Dr. Torsten Hombeck was appointed as Chief Financial Officer at Aspira Women's Health Inc..

“As previously announced, Dr. Torsten Hombeck will begin his service as the Company’s Chief Financial Officer on June 15, 2023.”

Marlene McLennan departed as Interim Chief Financial Officer at Aspira Women's Health Inc..

“Effective May 31, 2023, Marlene McLennan’s term as Interim Chief Financial Officer of Aspira Women’s Health Inc. (the “Company”) has come to a close, pursuant to her Employment Agreement with the Company.”

Dr. Winfred Parnell was appointed as director at Aspira Women's Health Inc..

“On June 1, 2023, the Company’s Board of Directors (the “Board”) appointed Dr. Winfred Parnell as a director, effective immediately.”

Torsten Hombeck was appointed as Chief Financial Officer at Aspira Women's Health Inc..

“appointed Tortsten Hombeck, Ph.D. as the Company’s Chief Financial Officer, effective as of June 15, 2023”

Aspira Women's Health Inc. reported the three months ended March 31, 2023 results: revenue $2.3 million. Guidance reaffirmed.

“regardless of any incorporation by reference language in such filing.  --- EX-99.1 (EX-99.1) --- 2023-05-11 8K Ex 991 Exhibit 99 .1 First Quarter total product revenue of $2.3 million, an increase of 26% year-over-year  First Quarter OvaSuite volume of 6,259 units, an increase of 29% year-over-year  First Quarter cash used in operations of $5.7 million, a”

Aspira Women's Health Inc.: Effected a one-for-fifteen reverse stock split of common stock pursuant to a Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation (effective 2022-05-11).

“On May 11, 2023, Aspira Women’s Health Inc. (the “Company”) filed a Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation, or the Amendment, to effect a one-for-fifteen (1:15) reverse stock split of our outstanding common stock, effective as of May 11, 2022, or the Reverse Stock Split.”

Aspira Women's Health Inc. shareholders approved Ratification of the Selection of BDO USA, LLP as the Company’s Independent Registered Public Accounting Firm for the Year Ending December 31, 2023 at the 2023-05-09 meeting.

“Proposal 6: Ratification of the Selection of the Company’s Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection of BDO USA, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023, as set forth below:”

Aspira Women's Health Inc. shareholders approved Approval of an Amendment to the Company’s Certificate of Incorporation to Effect a Reverse Stock Split of Outstanding Common Stock at a ratio between one-for-ten and one-for-twenty at the 2023-05-09 meeting.

“Proposal 5: Approval of an Amendment to the Company’s Certificate of Incorporation to Effect a Reverse Stock Split of the Company’s Outstanding Common Stock The Company’s stockholders approved a proposed amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.001 per share, at a ratio of between one-for-ten and one-for-twenty, which such ratio will be selected at the sole discretion of the Company’s Board of Directors at any whole number in the above range, as set forth below:”

Aspira Women's Health Inc. shareholders approved Approval of an Amendment to the Aspira Women’s Health Inc. 2019 Stock Incentive Plan to increase authorized shares by 5,000,000 and increase incentive stock option limit to 30,492,283 shares at the 2023-05-09 meeting.

“Proposal 4: Approval of an Amendment to the Aspira Women’s Health Inc. 2019 Stock Incentive Plan The Company’s stockholders approved an amendment to the Company’s 2019 Stock Incentive Plan (the “2019 Plan”) to increase the number of shares of common stock authorized to be granted under the 2019 Plan by 5,000,000 shares and increase the maximum number of awards that may be granted as incentive stock options under the 2019 Plan to a total of 30,492,283 shares, as set forth below:”

Aspira Women's Health Inc. shareholders approved Advisory Vote on the Frequency of Future Advisory Votes to Approve the Compensation of the Company’s Named Executive Officers at the 2023-05-09 meeting.

“Proposal 3: Advisory Vote on the Frequency of Future Advisory Votes to Approve the Compensation of the Company’s Named Executive Officers The Company’s stockholders advised that they were in favor of holding future advisory votes on the compensation of the Company’s named executive officers every [one] year, as set forth below:”

Aspira Women's Health Inc. shareholders approved Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers at the 2023-05-09 meeting.

“Proposal 2: Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on March 30, 2023, as set forth below:”

Aspira Women's Health Inc. shareholders approved Election of six nominees for director for a one-year term expiring at the 2024 annual meeting at the 2023-05-09 meeting.

“Proposal 1: Election of Directors The Company’s stockholders elected each of the Company’s six nominees for director for a one-year term expiring at the Company’s 2024 annual meeting of stockholders and until their successors are elected and qualified, as set forth below:”

Aspira Women's Health Inc. entered into Registration Rights Agreement with Lincoln Park Capital Fund, LLC (effective 2023-03-28).

“(the “Company”) and Lincoln Park Capital Fund, LLC (“Lincoln Park”) entered into a purchase agreement (the “Purchase Agreement”) and a registration rights agreement (the “Registration Rights Agreement”), pursuant to which the Company has the right, in its sole discretion, to sell to Lincoln Park shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), having an aggregate value of up to $10,000,000 (the “Purchase Shares”), subject to certain limitations and conditions set forth in the Purchase Agreement.”

Aspira Women's Health Inc. entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at up to $10,000,000 (effective 2023-03-28).

“On March 28 , 202 3, Aspira Women’s Health Inc. (the “Company”) and Lincoln Park Capital Fund, LLC (“Lincoln Park”) entered into a purchase agreement (the “Purchase Agreement”)”

Aspira Women's Health Inc. reported the year ended December 31, 2022 results: revenue $8.2 million.

“Total revenue was $8.2 million for the year ended December 31, 2022, an increase of 20% compared to $6.8 million for the same period in 2021.”

Aspira Women's Health Inc. reported the three months ended December 31, 2022 results: revenue $2.2 million.

“Total revenue for the three months ended December 31, 2022 was $2.2 million, an increase of 16% compared to $1.9 million for the same period in 2021.”

Valerie Palmieri resigned as Executive Chair at Aspira Women's Health Inc..

“Ms. Palmieri’s term as Executive Chair of the Company concluded on March 1, 2023.”

Dr. Robert Auerbach changed role as Lead Independent Director at Aspira Women's Health Inc..

“Dr. Robert Auerbach stepped down as the Company’s Lead Independent Director, effective as of March 1, 2023.”

Dr. Veronica G.H. Jordan was appointed as Chair of the Board at Aspira Women's Health Inc..

“the board of directors (the “Board”) of Aspira Women’s Health Inc. (the “Company”) appointed Dr. Veronica G.H. Jordan as the Chair of the Board , effective as of March 1, 2023.”

Aspira Women's Health Inc.: Increased authorized common shares from 150,000,000 to 200,000,000, and total authorized shares to 205,000,000 (effective 2023-02-06).

“On February 6, 2023, Aspira Women’s Health Inc. (the “Company”) filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Fourth Amended and Restated Certificate of Incorporation, as amended, to increase the authorized number of shares of the Company’s common stock from 150,000,000 shares to 200,000,000 shares, and accordingly to increase the total number of shares that the Company is authorized to issue to 205,000,000.”

Aspira Women's Health Inc. shareholders approved Increase in authorized shares of common stock from 150,000,000 to 200,000,000 at the 2023-02-06 meeting.

“Proposal 1: Increase in Authorized Shares The Company’s stockholders approved an amendment to the Company’s Fourth Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of the Company’s common stock from 150,000,000 shares to 200,000,000 shares, and accordingly to increase the total number of shares that the Company is authorized to issue to 205,000,000. The final voting results were as follows: FOR AGAINST ABSTENTIONS BROKER NON-VOTES 93,255,545 1,238,679 167,583 0”

Aspira Women's Health Inc. updated its the year ended December 31, 2022 guidance (reaffirmed).

“Aspira Women's Health Inc. issued a press release announcing certain operational metrics for the fourth quarter of 2022.”

Aspira Women's Health Inc. updated its the three months ended December 31, 2021 guidance (reaffirmed).

“Aspira Women's Health Inc. issued a press release announcing certain operational metrics for the fourth quarter of 2022.”

James T. LaFrance resigned as Director at Aspira Women's Health Inc..

“On December 15, 2022, James T. LaFrance resigned from the board of directors (the “ Board ”) of the Company, effective immediately.”

James T. LaFrance resigned as Director at Aspira Women's Health Inc..

“On December 15, 2022, James T. LaFrance resigned from the board of directors (the “ Board ”) of Aspira Women’s Health Inc., effective immediately.”

Aspira Women's Health Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“November 29, 2022, Aspira Women’s Health Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) that the Company has been granted an additional 180 calendar days, or until May 29, 2023 (as the first trading day following such period), to regain compliance with the minimum closing bid price of $1.00 per share, as is required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). As the Company previously reported on that cert”

Marlene McLennan was appointed as interim Chief Financial Officer at Aspira Women's Health Inc..

“the Board of Directors of Aspira Women’s Health Inc. (the “Company”) appointed Marlene McLennan as the Company’s interim Chief Financial Officer, effective as of December 1, 2022.”

Aspira Women's Health Inc. reported the third quarter ended September 30, 2022 results: revenue $2,037,000.

“wish Bob all the best in his future endeavors.”   Highlights of Third Quarter 2022 vs. Third Quarter 2021 · Product revenue for the three months ended September 30, 2022 was $2,037,000 compared to $1,617,000 for the same period in 2021, an increase of 26%. The number of Ova1Plus tests performed during the quarter increased 29% to 5,524 compared to 4,281 for the”

Nicole Sandford was appointed as President and Chief Executive Officer at Aspira Women's Health Inc..

“On February 23, 2022, the Board appointed Nicole Sandford, a current director on the Board, as the Company’s President and Chief Executive Officer, effective as of March 1, 2022.”

Valerie B. Palmieri was appointed as Executive Chairperson at Aspira Women's Health Inc..

“On February 23, 2022, the board of directors (the “Board”) of Aspira Women’s Health Inc. (the “Company”) appointed Valerie B. Palmieri as its Executive Chairperson, effective as of March 1, 2022.”

Sandra Brooks resigned as director at Aspira Women's Health Inc..

“On October 30, 2021, Sandra Brooks, M.D., M.B.A., a director of Aspira Women’s Health Inc. (the “Company”), resigned from the Company’s board of directors.”